Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

Peking University Peoples Hospital

🇨🇳China

Country: 🇨🇳China

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Fucoidan in the Treatment of Active Rheumatoid Arthritis

Not Applicable

Not yet recruiting

Conditions: Arthritis, Rheumatoid

First Posted Date: 2025-07-01

Last Posted Date: 2025-07-01

Lead Sponsor: Peking University People's Hospital

Target Recruit Count: 76

Registration Number: NCT07045896

The Impact of Different Sedation Regimens on Hemodynamics in Patients Undergoing Mechanical Ventilation With Shock

Not yet recruiting

Conditions: Mechanically Ventilated Patients With Shock

First Posted Date: 2025-06-25

Last Posted Date: 2025-06-25

Lead Sponsor: Peking University People's Hospital

Target Recruit Count: 50

Registration Number: NCT07037615

Observation and Study on the Application of Different Analgesic Regimens in Critically Ill Patients Without Mechanical Ventilation

Not yet recruiting

Conditions: Patients With Moderate to Severe Pain Requiring Analgesic Medications

First Posted Date: 2025-06-22

Last Posted Date: 2025-06-22

Lead Sponsor: Peking University People's Hospital

Target Recruit Count: 80

Registration Number: NCT07031453

Comparison of ultraSound, Abbreviated MRI witH and Without HBP aS mOdalities for HCC suRveillance in patienTs With High Risk

Not Applicable

Not yet recruiting

Conditions: Hepatocellular Carcinoma (HCC)
Magnetic Resonance Imaging (MRI)
Randomized Controlled Trial

First Posted Date: 2025-06-08

Last Posted Date: 2025-06-08

Lead Sponsor: Peking University People's Hospital

Target Recruit Count: 1389

Registration Number: NCT07010588

Locations: 🇨🇳
Peking University People's Hospital, Beijing, Beijing, China
🇨🇳
The First Affiliated Hospital of Army Medical University, Chongqing, Chongqing, China
🇨🇳
Handan Central Hospital, Handan, Hebei, China

and more 9 locations

Long-Term Outcomes in SLE at Peking University People's Hospital

Recruiting

Conditions: Systemic Lupus Erythematosus

First Posted Date: 2025-06-05

Last Posted Date: 2025-06-05

Lead Sponsor: Peking University People's Hospital

Target Recruit Count: 1000

Registration Number: NCT07005479

Locations: 🇨🇳
Department of Rheumatology and Immunology, Peking University People's Hospital, Beijing, Beijing, China

Therapy of Niacin for Rheumatoid Arthritis

Phase 2

Not yet recruiting

Conditions: Rheumatoid Arthritis (RA)

Interventions: Drug: niacin sustained release capsules
Drug: Placebo

First Posted Date: 2025-06-04

Last Posted Date: 2025-06-04

Lead Sponsor: Peking University People's Hospital

Target Recruit Count: 60

Registration Number: NCT07004725

Reduced ATG Plus Mini PTCy for GVHD Prophylaxis in Haplo-SCT

Phase 2

Not yet recruiting

Conditions: Myelodysplastic Syndrome
Acute Leukemia

Interventions: Drug: Reduced ATG plus mini PTCy

First Posted Date: 2025-05-22

Last Posted Date: 2025-05-22

Lead Sponsor: Peking University People's Hospital

Target Recruit Count: 40

Registration Number: NCT06984536

Locations: 🇨🇳
Peking University People'S Hospital, Beijing, China

Clinical Study on the Targeted CD19 Universal CAR-T Cell Injection (RD06-04) for the Treatment of IIM and AAV

Early Phase 1

Not yet recruiting

Conditions: Idiopathic Inflammatory Myopathies
ANCA-Associated Vasculitis

Interventions: Drug: RD06-04 Cell Injection Infusion

First Posted Date: 2025-05-22

Last Posted Date: 2025-05-22

Lead Sponsor: Peking University People's Hospital

Target Recruit Count: 12

Registration Number: NCT06986018

Locations: 🇨🇳
Peking University People's Hospital, Beijing, China

Efficacy and Safety of Low-dose IL-2 in SLE Patients With CMV Viremia

Phase 2

Not yet recruiting

Conditions: SLE (Systemic Lupus)
CMV

Interventions: Drug: Interleukin-2 (IL-2)
Drug: Ganciclovir (GCV)

First Posted Date: 2025-05-14

Last Posted Date: 2025-05-14

Lead Sponsor: Peking University People's Hospital

Target Recruit Count: 100

Registration Number: NCT06971913

Locations: 🇨🇳
Peking University People's Hospital, Beijing, Bejing, China

ctDNA-Guided De-Escalation of Adjuvant Chemotherapy With Dalpiciclib in HR-Positive/HER2-Negative Breast Cancer

Phase 2

Not yet recruiting

Conditions: Hormone Receptor-Positive Breast Cancer
High-risk Breast Cancer
Early-Stage Breast Cancer
HER2-negative Breast Cancer
ctDNA Monitoring
Breast Cancer Early Stage Breast Cancer (Stage 1-3)

Interventions: Drug: Taxane-Based Neoadjuvant Chemotherapy
Drug: Dalpiciclib + Aromatase Inhibitor with ctDNA-Guided Therapy

First Posted Date: 2025-05-14

Last Posted Date: 2025-05-14

Lead Sponsor: Peking University People's Hospital

Target Recruit Count: 393

Registration Number: NCT06970912

Locations: 🇨🇳
Peking University People's Hospital, Beijing, Beijing, China

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy